bpc 157 ulcer: Frequently asked questions

Switch to subcutaneous or consider increasing oral dose 50–100×. BPC-157's bioavailability via oral route is estimated at 0.1–1% due to gastric acid degradation and peptidase activity in the small intestine. A 10 mg/kg oral dose approximates the tissue exposure achieved by 10 µg/kg subcutaneous in rodent models. Meaning human-equivalent oral dosing would require proportionally massive amounts to match injection efficacy.

Consult a gastroenterologist for endoscopy and H. pylori testing. Persistent ulcer symptoms suggest either an undiagnosed infection, a deeper mucosal defect, or a condition BPC-157 doesn't address (such as Zollinger-Ellison syndrome or gastric malignancy). Research peptides are not substitutes for medical diagnosis. They're tools for biological research, not therapeutic interventions. If symptoms worsen or you develop severe abdominal pain, vomiting blood, or black tarry stools, seek emergency care immediately.

This is consistent with published data. Omeprazole co-administration showed no synergy in multiple trials. The suspected mechanism: PPIs alter intragastric pH to 6–7, which may interfere with growth factor receptor endocytosis and recycling. If you're using acid suppression, H2 blockers (ranitidine, famotidine) demonstrated better compatibility with BPC-157's cytoprotective effects without disrupting receptor signalling.

Switch to COX-2 selective inhibitors (celecoxib) or add a proton pump inhibitor (omeprazole 20mg daily). Both are FDA-approved strategies with documented efficacy in preventing NSAID-induced gastric ulcers. BPC-157 has shown cytoprotective effects in animal models when co-administered with NSAIDs, but no human data exists to support its use as a preventive agent. The mechanism makes biological sense. BPC-157 preserves mucosal integrity even when prostaglandin synthesis is suppressed. But unproven therapies carry unknown risk.

Increase dosing frequency from once daily to twice daily at the same per-dose amount. Split 10 µg/kg into 5 µg/kg every 12 hours. Preclinical data from the University of Zagreb showed that maintaining stable plasma levels through divided dosing improved chronic ulcer healing rates by 18–25% versus single daily bolus. The mechanism likely involves sustained VEGFR-2 activation rather than pulsatile signalling.

The evidence for IBD is even thinner than for gastric ulcers. A handful of studies show reduced colonic inflammation in TNBS-induced colitis models in rats, but inflammatory bowel disease in humans involves immune dysregulation far more complex than chemically induced rodent colitis. BPC-157 has no established role in Crohn's disease or ulcerative colitis management. Biologics like infliximab and vedolizumab have decades of human trial data and FDA approval for these indications.